凝血因子药物市场分析

发布时间：2018-12-12 16:42

【摘要】：凝血因子是一类特殊的药物,是血友病等血液疾病的治疗药物,目前已经成为血液制品的重要组成部分。国外已经有二十多种重组凝血因子药物上市,2015年全球重组凝血因子药物的市场规模已经达到78.54亿美元,未来还将持续增长,Baxalta公司的重组凝血因子产品销售额位居全球首位,达到28.40亿美元。国外有多种重组凝血因子处于研发阶段,其中长效重组凝血因子将成为新的市场增长点。国内各类凝血因子药物的批签发状况良好,且随着国家发展和改革委员会取消血液制品最高零售价,各类产品价格均有不同幅度增长,其中人纤原蛋白原增长幅度最高,达到189%。国产凝血因子市场空间巨大,但存在产品供给和研发力度不足等问题,发展受到限制,必须改革行业管理制度、提高血浆分离技术、加强重组产品研发。
[Abstract]:Coagulation factor is a kind of special medicine, and it is the treatment of hemophilia and other blood diseases. At present, it has become an important part of blood products. More than 20 recombinant coagulation factor drugs have already been put on the market abroad. The global market size of recombinant coagulation factor drugs has reached 7.854 billion US dollars in 2015, and will continue to grow in the future. Baxalta has the largest sales of recombinant coagulation factor products in the world, at $2.84 billion. There are many kinds of recombinant coagulation factors in foreign countries, among which long-acting recombinant coagulation factors will become a new market growth point. The approval and issuance of various kinds of clotting factor drugs in China is in good condition, and with the National Development and Reform Commission cancelling the highest retail price of blood products, the prices of all kinds of products have increased by varying degrees, among which the increase in human fibrinogen is the highest. Reach 1899. The market space of domestic coagulation factor is huge, but there are some problems such as insufficient product supply and R & D, so the development is restricted. It is necessary to reform the industry management system, improve plasma separation technology, and strengthen the research and development of recombinant products.
【作者单位】：江西省科学院科技战略研究所;南昌高新技术产业开发区管理委员会;
【基金】：江西省软科学资助项目(20151BBA10065,20161ACA10023)
【分类号】：Q81

【参考文献】